Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Inspira Technologies Oxy BHN Ltd (IINN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: IINN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.23% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.78M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 2.12 | 52 Weeks Range 0.40 - 1.60 | Updated Date 06/30/2025 |
52 Weeks Range 0.40 - 1.60 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.03% | Return on Equity (TTM) -219.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16652384 | Price to Sales(TTM) - |
Enterprise Value 16652384 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.15 | Shares Outstanding 25619300 | Shares Floating 24090830 |
Shares Outstanding 25619300 | Shares Floating 24090830 | ||
Percent Insiders 8.75 | Percent Institutions 5.17 |
Analyst Ratings
Rating 1 | Target Price 2 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Inspira Technologies Oxy BHN Ltd
Company Overview
History and Background
Inspira Technologies Oxy BHN Ltd. (IINN) was founded in 2018. It focuses on developing breakthrough respiratory support technology. Recent milestones include progressing their ART device towards regulatory approval and expanding their intellectual property portfolio.
Core Business Areas
- Respiratory Support Technology: Development of innovative respiratory support devices, including the ART system, designed to minimize the need for invasive mechanical ventilation.
Leadership and Structure
Dagi Ben-Noon is the CEO. The company has a board of directors and operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- ART (Augmented Respiration Technology) System: The ART system is a non-invasive respiratory support device intended to prevent the need for invasive mechanical ventilation. Market share is currently 0% as the product is pending regulatory approval. Competitors include traditional ventilator manufacturers like Medtronic (MDT), Philips (PHG), and Getinge (GETI-B.ST).
Market Dynamics
Industry Overview
The respiratory support market is experiencing growth due to factors such as aging populations, increasing prevalence of respiratory diseases, and advancements in technology. The COVID-19 pandemic also significantly impacted the demand for respiratory support devices.
Positioning
Inspira Technologies aims to disrupt the respiratory support market by offering a less invasive alternative to traditional ventilators. Their competitive advantage lies in the ART system's potential to reduce the need for intubation.
Total Addressable Market (TAM)
The global respiratory devices market is projected to reach billions of dollars. Inspira Technologies targets a segment of this market with its ART system, aiming to capture a significant portion by providing non-invasive alternatives to mechanical ventilation.
Upturn SWOT Analysis
Strengths
- Innovative technology (ART system)
- Potential to reduce invasive ventilation
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful regulatory approval
- Limited revenue generation currently
- Small size compared to established competitors
- High cash burn
Opportunities
- Expanding market for respiratory support devices
- Potential partnerships with hospitals and healthcare providers
- Growing awareness of the risks associated with invasive ventilation
Threats
- Regulatory hurdles and delays
- Competition from established medical device companies
- Technological advancements by competitors
- Market acceptance of new technology
- Dependence on third party manufacturers
Competitors and Market Share
Key Competitors
- MDT
- PHG
- GETI-B.ST
Competitive Landscape
Inspira Technologies has the potential to disrupt the market with its ART system. However, it faces significant competition from established players with greater resources and existing market share. Their advantage rests on their novel technology and non-invasive approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is pre-revenue. Growth depends on regulatory approval and market adoption of the ART system.
Future Projections: Future projections depend on successful regulatory approval and commercialization of the ART system. Analyst estimates vary depending on these factors.
Recent Initiatives: Recent initiatives include clinical trials, regulatory submissions, and partnerships to expand manufacturing capabilities.
Summary
Inspira Technologies is a pre-revenue stage company with an innovative respiratory support technology. Its future hinges on regulatory approval and successful commercialization of its ART system. It faces competition from established players and is subject to regulatory risks. They will need to closely manage their cash burn to reach commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (general information)
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. Financial data is approximate, as precise values from SEC filings and investor relations are not accessible. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inspira Technologies Oxy BHN Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-07-14 | Co-Founder, CEO & Director Mr. Dagi Shahar Ben-Noon | ||
Sector Healthcare | Industry Medical Devices | Full time employees 37 | Website https://inspira-technologies.com |
Full time employees 37 | Website https://inspira-technologies.com | ||
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure in Israel. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.